Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PsychoGenics Inc.

www.psychogenics.com

Latest From PsychoGenics Inc.

Blonanserin On Course As First Atypical For Adolescent Schizophrenia In Japan

Dainippon drug likely to become first atypical to be approved for adolescent schizophrenia in Japan following planned filing based on positive new Phase III results.

Japan Clinical Trials

Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Tech Transfer Deals, March 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced January through February 2016.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Transgenics
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • PGI Drug Discovery LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PsychoGenics Inc.
  • Senior Management
  • Emer Leahy, PhD, Pres. & CEO
    William C Fasnacht, CFO & COO
    Bavani Shankar, VP, Corp. Dev.
    Mark A Varney, PhD, CSO
  • Contact Info
  • PsychoGenics Inc.
    Phone: (914) 406-8019
    765 Old Saw Mill River Rd.
    Tarrytown, NY 10591
    USA
UsernamePublicRestriction

Register